The multilayered postconfluent cell culture as a model for drug screening

Critical Reviews in Oncology/Hematology

Volumn 36, Issue 2-3, 2000, Pages 141-157

  Padrón, José M ^a,b   Van Der Wilt, Clasina L ^a   Smid, Kees ^a   Smitskamp Wilms, Evelien ^a   Backus, Harold H J ^a   Pizao, Paolo E ^a,c   Giaccone, Giuseppe ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b DSM RESEARCH   (Netherlands)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Anticancer drug screening; Postconfluent cultures; Three dimensional cell cultures

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; MILTEFOSINE; NUCLEOTIDE; TOMUDEX; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PHARMACODYNAMICS; REVIEW;

ANIMAL; CELL COMMUNICATION; CELL CULTURE; CELL DIVISION; DRUG EVALUATION, PRECLINICAL; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0033795717     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00083-4     Document Type: Review

References (98)

1. Status of the NCI preclinical antitumour drug discovery screen
2. Screening at the National Cancer Institute: basic concepts
3. Production and characterization of multiple-layered perfusion cultures
4. Postconfluency MDCK monolayers as an in vitro model of soild tumour chemosensitivity
5. Mechanism of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion
6. Comparative chemosensitivity of exponential-versus plateau-phase cells in both in vitro and in vivo systems
7. Differential killing efficacy of twenty antitumour drugs on proliferating and nonproliferating tumour cells
8. Plateau-phase cultures: an experimental model for identifying drugs that are bioactivated within the microenvironment of solid tumours
9. Sustained growth and three-dimensional organization of primary mammary tissues in collagen gels
10. Significance of three-dimensional organization of primary mammary tumour epithelial cells embedded in collagen gels
11. Assessing tumour drug sensitivity by a new in vitro assay which preserves tumour heterogeneity and supopulation interactions
12. A sponge matrix method for tissue cultures. Formation of organized aggregates of cell in vitro
13. Three-dimensional gel-supported native-state histoculture for evaluation of tumour-specific pharmacological activity: principles, practice and possibilities
14. Cellular viability in human tumour microorgan cultures: in situ quantitation by image processing
15. Growth of nodular carcinomas in rodents compared with the multi-cell spheroids in tissue culture
16. Cell and environment in tumour microregions: the multicell spheroid model
17. Importance of critical metabolites and cellular interactions in the biology of microregions of tumours
18. Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumours in vivo. Complete growth inhibition but not regression
19. Destruction of WiDr multicellular tumour spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations
20. Three-dimensional histocultures: origins and applications in cancer research
21. In vitro sensitivity assays in cancer: a review, analysis, and prognosis
22. Growth, morphology and chemosensitivity studies of postconfluent cells cultures in 'V'-bottomed microtiter plates
23. In vitro chemosensitivity testing of multilayered microcultures
24. Multicellular tumour spheroid formation by breast cancer cells isolated from different sites
25. Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid
26. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumour cell cultures
27. Chemotherapy of human colon cancer xenografts in athymic nude mice
28. Effect of glutamine deprivation and glutamate or ammonium chloride addition on growth rate, metabolism and differentiation of human colon cancer cell line HT-29
29. Epithelial polarity, villin expression, and enterocytic differentiatin of cultured human colon carcinoma cells: a survey of twenty cell lines
30. Enterocytic differentiation of cultured human colon cancer cells by replacement of glucose by galactose in the medium
31. Cell differentiation and dome formation in polarized epithelial cell monolayers
32. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells
33. Monoclonal antibodies to human colorectal epithelium: markers for differntiation and tumour characterization
34. Oxygenation and differentiation in multicellular spheroids of human colon carcinoma
35. New colorimetric cytotoxicity assay for anticancer-drug screening
36. Comparison of the sulforhodamine B protin and the tetrazolium (MTT) assays for in vitro chemosensitivity testing
37. Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines
38. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions
39. S1-phase cells of the leukemic cell cycle sensitive to 1-β-D-arabinofuranosylcytosine at a high-dose level
40. Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures
41. Confluent-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells
42. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub-and postconfluent tumour cell cultures
43. c-myc: Evidence for multiple regulatory functions
44. Differential expression of DNA topoisomerases I and II duing the eukaryotic cell cycle
45. Regulation of DNA topoisomerases during cellular differentiation
46. Proliferation-dependent regulation of DNA toposiomerase II in cultured human cells
47. Increased activity and expression of NAD(P)H:quinone acceptor oxidoreductase in confluent cell cultures and within multicellular spheroids
48. Comparative in vitro chemosensitivity of DLD-1 human colon adenocarcinoma monolayers and spheroids to the +novel indoloquinone EO9
49. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours
50. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil
51. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor L1210 tumour cell growth in vitro and in vivo
52. Biochemical and cellular pharmacology of 1843U89, a novel quinazoline inhibitor of thymidylate synthase
53. Posttranscriptional regulation of thymidylate synthase gene expression
54. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme
55. Expression of key enzymes of purine and pyrimidine metabolism in a hepatocyte-derived cell line at different phases of the growth cycle
56. Evaluation of the antitumour activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)
57. Three-dimensional cell cultures as a model system to evaluate the biological avtivity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)
58. Postconfluent multilayered cell line cultures for selective screening of gemcitabine
59. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity
60. Membrane transport of methotrexate in a squamous carcinoma cell line adapted to low folate concentrations
61. The current status of camptothecin analogues as antitumour agents
62. Data display and analysis strategies for the NCI disease-oriented in vitro drug screen
63. The median-effect plot and the combination index for quantitation of synergism and antagonism
64. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (gemcitabine) against human head and neck cancer
65. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
66. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine)
67. Phase II study of gemcitabine in previously-treated ovarian cancer patients
68. Synthesis of water-soluble aminoalkylcamptothecin analogues: inhibition of topoisomerase I and antitumour activity
69. Comparative efficacy of topotecan, irinotecan, camptothecin and 9-aminocamptothecin in preclinical tumour models
70. Surgical adjuvant therapy in colon carcinoma: a human tumour spheroid model for evaluating radiation sensitizing agents
71. A new method for the three-dimensional in vitro growth of human cancer cells
72. The role of NAD(P)H: quinone reductase (EC1.6.99, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9
73. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
74. The assessment of bioreductive drug toxicity in vitro and experimental tumours in vivo
75. How to kill cancer cells: membrane and cell signalling as targets in cancer chemotherapy
76. The cell membrane and cell signals: new targets for novel anticancer drugs
77. Synergistic interaction between cisplatin and gemcitabine in vitro
78. Combination chemotherapy studies with gemcitabine
79. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines
80. Antitumour activity of gemcitabine in combination with cisplatin against the human NSCLC xenograft Calu-6
81. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts
82. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice
83. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC). A phase II study
84. New drugs in non-small cell lung cancer: an overview
85. The role of folates in the chemosensitivity to tomudex, LY231514 and 5-fluorouracil/leucovorin of murine tumour models
86. New targets for pyrimidine antimetabolites for the treatment of solid tumours. 1. Thymidylate synthase
87. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9
88. Modulation of fluorouracil by leucovorin in patients with advanced colorectal caner: evidence in terms of response rate
89. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue
90. Tomudex(TM) (ZD1694) - from concept to care, a programme in rational drug discovery
91. Phase II preclinical drug screening in human tumour xenografts: a first European multicenter collaborative study
92. Preclinical phase II studies in human tumour xenografts: a European multicenter follow-up study
93. Modulation of multidrug resistance: at the threshold